A new trial of tadalafil (Cialis), a drug that dilates blood vessels, is now under way at Cedars-Sinai Medical Center in Los Angeles for men with Becker muscular dystrophy (BMD) who meet study criteria.
The new study is an outgrowth of previous research on tadalafil in BMD, which showed that there is a blood flow abnormality in men with the disease and that a single oral dose of tadalafil reverses this abnormality.
"We now wish to extend these exciting research findings to see if tadalafil can also improve exercise tolerance — allowing patients with BMD to exercise longer without stressing the working muscles," said Ronald Victor, a cardiovascular disease specialist and the principal investigator for the new trial.
About the tadalafil study
The study involves two visits to Cedars-Sinai, separated by at least one week, and each consisting of three study days. For example, participants can arrive on a Sunday and leave on a Wednesday. There is no cost to participants, and Cedars-Sinai will cover travel and lodging expenses, as well as $150 per study day ($900 total).
Prospective participants must:
Prospective participants must not:
For more information
To learn more about blood flow and muscular dystrophy, see Enhancing Blood Flow to Exercising Muscles.